Forecast

The analysts' average price target is €245.98 (+130.92%). The median is €245.98 (+130.92%).

Buy	3
Hold	2
Sell	0

News Go to news feed

Inhibrx reports positive phase‑2 results for INBRX-106 with significantly higher response rate

Inhibrx published interim results from the phase‑2 portion of the HexAgon study: the combination of INBRX-106 with pembrolizumab achieved a confirmed objective response rate of 44.0% versus 21.4% with pembrolizumab alone (absolute increase 22.6%). In the evaluable population, 11 of 25 patients in the combination arm responded, including three complete remissions, versus 6 of 28 in the control arm. Peripheral blood analyses showed up to 15‑fold increases in CD8+/CD4+ T‑cell proliferation with the combination versus up to 2.5‑fold with pembrolizumab alone; the safety profile was manageable. Inhibrx expects PFS data in Q4 2026 and plans to start the phase‑3 portion in Q3 2026. » More on de.investing.com
Inhibrx Biosciences hits new all-time high after over 600% rally

Shares of Inhibrx Biosciences rose to $152.22, bringing market capitalization to about $1.23 billion after a year-to-date gain of more than 608%. Over the past six months the stock gained roughly 167% and is trading near its 52-week high, while InvestingPro rates the shares as overvalued relative to its fair-value estimate. The company reported interim results from the phase‑1/2 study of Ozekibart in combination with FOLFIRI in advanced colorectal cancer, showing an objective response rate of 20%, well above standard‑therapy rates. Despite the price gains, Inhibrx remains unprofitable (EPS -$9.04), and analysts such as Stifel maintain a buy rating with a $150.00 price target, highlighting the potential of INBRX-106. » More on de.investing.com
Inhibrx reports progress in multiple cancer studies

Inhibrx has recruited 46 of 60 patients in the phase‑2 study of INBRX‑106 for head and neck cancer; study completion is expected in Q1 2026. Recruitment of 34 patients in the phase‑1/2 study of INBRX‑106 plus Keytruda in checkpoint‑inhibitor‑refractory non‑small cell lung cancer is complete, with meaningful data expected in H2 2026. The Ozekibart program showed a 52% reduction in the risk of progression or death in the ChonDRAgon study, sparking increased interest; additional Ozekibart data and ongoing recruitments are scheduled for 2026. Financially, the company operates with moderate debt and liquid assets that are exceeded by short‑term liabilities; if response rates persist, Inhibrx plans an FDA meeting in H2 2026. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2024, Inhibrx has already paid €0.79 in dividends. The last payout was in June 2024.

Financials

In the last quarter, Inhibrx had revenue of €0 and net profit of -€32.11M

(EUR)	Jun 2026	YoY
Revenue	0	100.00%
Gross profit	0	100.00%
Net profit	-32.11M	32.09%
EBITDA	-26.7M	26.66%

Fundamentals

Metric	Value
Market capitalization	€1.56B
Number of shares	14.67M
52-week high/low	€134.03 - €22.60
Dividends	No
Beta	3.52
P/E ratio	-13.90
PEG ratio	-0.75
P/B ratio	-36.50
P/S ratio	0.00

Company profile

Inhibrx, Inc. ist ein Biotechnologieunternehmen in der klinischen Phase und konzentriert sich auf die Entwicklung einer Pipeline neuartiger biologischer Therapiekandidaten. Zu den therapeutischen Kandidaten des Unternehmens gehört INBRX-109, ein tetravalenter Agonist des Todesrezeptors 5, der sich in klinischen Phase-2-Studien zur Behandlung von Krebserkrankungen wie Chondrosarkom, Mesotheliom und Pankreas-Adenokarzinom befindet; INBRX-105, ein tetravalenter konditionaler Agonist des programmierten Todesliganden 1 und ein konditionaler Agonist von 4-1BB, der sich in klinischen Studien der Phase 1 zur Behandlung von Patienten mit lokal fortgeschrittenen oder metastasierten soliden Tumoren befindet; und INBRX-101, ein therapeutischer Alpha-1-Antitrypsin (AAT)-Fc-Fusionsprotein-Kandidat, der sich in klinischen Studien der Phase 1 zur Verwendung bei der Behandlung von Patienten mit AAT-Mangel befindet. Außerdem bietet es INBRX-106 an, einen hexavalenten Agonisten von OX40 für eine Reihe von onkologischen Indikationen. Das Unternehmen wurde 2010 gegründet und hat seinen Hauptsitz in La Jolla, Kalifornien.